RxDoctor Payments Data

Elizabeth Rogan, PA

Surgical · Glens Falls, NYNPI 1376025502

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.1%), education and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Arthrex at 34.0% of the total. Reporting peaked in 2022 at $3,653 and has fallen 57.5% since, to $1,553 in 2025. Among surgical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,500in general payments, 2019–2025

Across 218 payments — averaging $38.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$3K
  • Johnson & Johnson$1K
  • AbbVie$1K
  • Prodigy Surgical Distribution, Inc.$661
  • E.r. Squibb & Sons, L.L.C.$428
  • Novartis$335
  • plus $2K from 19 others

What the payments were for

  • Travel & lodging$96411%
  • Food & beverage$4,77156%
  • Education$2,76533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,500 in reported general payments places this provider in the 95th percentile of 1,544 surgical providers in New York.

See all surgical providers in New York

Medicare billing

Part B allowed, 2024
$95,662
Medicare patients
473
Services billed
1,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab31$116,362
OtezlaApremilast11$48,632
Clobetasol Propionate131$5,447
Tacrolimus64$4,612
Fluorouracil45$2,590
Betamethasone Dipropionate44$2,489
Luliconazole12$2,345
Calcipotriene23$2,156
Azelaic Acid17$1,971
Ketoconazole94$1,682
Triamcinolone Acetonide78$1,298
Metronidazole22$1,147
Clindamycin Phosphate29$1,051
Tretinoin11$728
Minoxidil84$543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$30$48,63211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,544 surgical providers in New York.

Other surgical in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →